Development of a novel prognostic score for breast cancer patients using mRNA expression of CHAC1

J Comp Eff Res. 2017 Oct;6(7):563-574. doi: 10.2217/cer-2017-0015. Epub 2017 Sep 19.


Aim: To develop a prognostic score for primary breast cancer patients integrating conventional predictors and the novel biomarker CHAC1 to aid adjuvant chemotherapy decisions.

Patients & methods: A prognostic score for overall survival was developed using: conventional predictors from a dataset of 1777 patients and the weight of CHAC1 mRNA expression from an independent dataset of 106 patients using multivariate Cox regression.

Results: The new score includes: CHAC1 mRNA expression, age, tumor size, HER2 neu status, lymph node status and degree of malignancy. Using a cut-off value of 11 score points, 10-year survival was 82% in low-risk (n = 34) and 43% in high-risk patients (n = 72). The addition of CHAC1 resulted in 16% reclassification.

Conclusion: Including CHAC1 in prognostic prediction may aid (and change) personalized treatment selection.

Keywords: CHAC1 mRNA; adjuvant chemotherapy; biomarker; breast cancer; decision aid; prognostic score.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Biomarkers, Tumor / metabolism*
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / mortality*
  • Chemotherapy, Adjuvant / mortality
  • Female
  • Humans
  • Middle Aged
  • Prognosis
  • RNA, Messenger / metabolism
  • Receptor, ErbB-2 / metabolism
  • Receptors, Estrogen / metabolism
  • gamma-Glutamylcyclotransferase / metabolism*


  • Biomarkers, Tumor
  • RNA, Messenger
  • Receptors, Estrogen
  • Receptor, ErbB-2
  • CHAC1 protein, human
  • gamma-Glutamylcyclotransferase